Gilead Sciences, Inc. $GILD Holdings Boosted by Noesis Capital Mangement Corp

Noesis Capital Mangement Corp increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 132,470 shares of the biopharmaceutical company’s stock after buying an additional 6,238 shares during the period. Gilead Sciences comprises about 2.3% of Noesis Capital Mangement Corp’s investment portfolio, making the stock its 18th largest position. Noesis Capital Mangement Corp’s holdings in Gilead Sciences were worth $19,745,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Motive Wealth Advisors acquired a new position in Gilead Sciences during the 3rd quarter worth $258,000. Leo Wealth LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $592,000. Apollon Wealth Management LLC grew its stake in Gilead Sciences by 2.5% in the third quarter. Apollon Wealth Management LLC now owns 39,561 shares of the biopharmaceutical company’s stock worth $5,897,000 after purchasing an additional 976 shares in the last quarter. Kingswood Wealth Advisors LLC grew its stake in Gilead Sciences by 9.6% in the third quarter. Kingswood Wealth Advisors LLC now owns 11,709 shares of the biopharmaceutical company’s stock worth $1,745,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Royal Palms Capital LLC bought a new stake in Gilead Sciences in the third quarter valued at about $207,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: An analyst raised the fiscal 2026 EPS forecast for Gilead, signaling improved expectations for the company’s earnings outlook. FY2026 EPS Forecast for Gilead Sciences Raised by Analyst
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide medicines. The transaction may support investor optimism about Gilead’s business-development strategy and longer-term growth opportunities in this emerging market. Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides
• Neutral Sentiment: Investors are preparing for Gilead’s third-quarter 2026 earnings report. Analysts are focused not only on revenue and EPS but also on operating metrics that could provide clues about product performance and the company’s outlook. Ahead of Gilead Q3 Earnings
• Neutral Sentiment: Recent coverage compares Gilead with Amgen as a dividend investment. Gilead offers a forward dividend yield above 2% and a lower payout ratio, although Amgen is reported to have stronger sales growth. Amgen vs. Gilead Sciences
• Negative Sentiment: The reported October short-interest data lists short interest at zero shares and a zero-day short-interest ratio despite describing a large increase. This apparent inconsistency limits its usefulness as a reliable signal of bearish positioning.

Gilead Sciences Trading Up 1.7%

GILD stock opened at $158.69 on Tuesday. The firm’s 50-day simple moving average is $148.84 and its 200 day simple moving average is $138.77. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 earnings per share. Analysts predict that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GILD. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Jefferies Financial Group restated a “buy” rating and set a $185.00 price objective on shares of Gilead Sciences in a research note on Friday. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Bank of America increased their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Finally, HSBC raised their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $159.81.

Insider Activity

In other news, Director Anthony Welters sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the sale, the chief executive officer owned 566,683 shares in the company, valued at approximately $83,812,415.70. This represents a 2.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock worth $15,877,860 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.